---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-071389"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:45:14.166594+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Verrica appoints Gavin Corcoran to board as Class I director

## Summary
- Dr. Corcoran appointed effective March 31, 2025; term expires at 2025 annual meeting.
- Granted option to purchase 17,502 shares at grant-date closing price; vests over 3 years.
- Receives $40,000 annual retainer; eligible for annual option of 20,000 shares.
- Currently Chief Development Officer of Formation Bio; former CMO of Allergan and Actavis.

## SEC filing metadata
- accession: 0001193125-25-071389
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/0001193125-25-071389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/d906738d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-071389
- JSON: https://secwatch.observer/filing/0001193125-25-071389.json
- Plain text: https://secwatch.observer/filing/0001193125-25-071389.txt

## Key facts
- Executive change
  Gavin Corcoran was appointed as Director at Verrica Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/0001193125-25-071389-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.